Dr Lal PathLabs Limited: Value Pick Stock Sept ’19, Update
Update
Q1 FY 2022-23 Earnings
Dr. Lal PathLabs Limited – a leading diagnostic and related healthcare service provider announced its financial results for the quarter ended June 30, 2022.
On a consolidated basis, the operating revenue of the company stood at INR 502.7 Cr for the Q1 FY23 as against INR 485.5 Cr for the period ended 31 March 2022, registering a growth of 3.54% Q-O-Q basis.
The revenue of the company for Q1 FY22 stood at INR 606.6 Cr, registering a fall of 17.13% Y-O-Y basis.
Non-Covid Revenue of the company increased by 25 percent in Q1 FY23 to INR 482 Cr v/s INR 386 Cr in Q1 FY22. Covid and Allied business contributed 4 percent to Revenue in Q1 FY23, and 36% in Q1 FY22.
Total Expenses of the Company –
INR 429.6 Cr as on 30 June 2022,
INR 441.4 Cr as on 30 June 2021,
INR 414 Cr as on 31 March 2022
Normalised EBITDA (after adjustment for stock-based compensation, CSR) for Q1 FY21 is at INR 126 crore (margins 25%) v/s INR 199 crore in the same quarter last year.
Profit After Tax for Q1 FY2022-23 stood at INR 58.2 Cr as compared to INR 133.7 Cr for Q1 FY21, registering a fall of 56.47% Y-O-Y basis. However, the Q-O-Q PAT of the company fell by 6.28% (INR 62.1 Cr for the period ended 31 March 2022)
An interim Dividend of INR 6 per equity share of Rs. 10 each has been approved by the Board of Dr. Lal PathLabs.
EPS of the company stood as follows –
INR 6.97 as on 30 June 2022,
INR 15.87 as on 30 June 2021,
INR 7.41 as on 31 March 2022
Daily Chart –
Shares of Dr. Lal PathLabs closed at INR 2137.15 (down 1.52%) with a volume of 6, 53,885 shares on the NSE.
Dr. Lal PathLabs Limited is a value pick stock of Finblab (given 3.5x returns, currently 2x returns)
Final Comment: The Company has posted a weak set of numbers for the quarter gone by, where PAT of the company was hit mainly by higher depreciation and other expenses. Keeping the company’s brand value and valuation (the stock is available at a 50 percent discount from its ATH) in mind, Finblab maintains a Positive view on the company.
Also Read: Q1 Numbers of APL Apollo
8 November 2019
Update:
Q2 FY 2019-20 Numbers
Dr. Lal PathLabs Limited – an international service provider of diagnostic and related healthcare tests, based in Delhi has posted its Q2 numbers today. Standalone quarterly numbers for the company are:
Revenue from operations stood at INR 351.20 crore in Sept ’19 up 14.32 percent year-on-year basis from INR 307.20 crore in Sept ’18. However, the quarter-on-quarter revenue grew by 8.23 percent (INR 324.50 crore for June ’19)
Quarterly Net Profit at INR 79.5 crore in September 2019 up 38.74 percent quarter-on-quarter basis from INR 57.3 crore in June 2019. However, Y-O-Y profit grew by 44.02 percent (INR 55.2 crore in September 2018)
Read: Superb Q2 numbers of GMM PFAUDLER LTD
At the Meeting, the Board of Directors have also declared an interim dividend of INR 6 per equity share (@ 60% on a face value of Rs. 10 per share) for the Financial Year 2019-20. Also, kindly take note that the Board has fixed November 21, 2019 as the record date for the payment of interim dividend.
Dr. Lal PathLabs EPS has increased to Rs. 9.65 in September 2019 from Rs. 6.95 in June 2019.
Dr. Lal PathLabs shares currently trading at INR 1452.90 on November 08, 2019 (NSE) and is trading above its 200 EMA (1175) and 50 EMA (1378)
Must Read: Finblab Value Pick Stock Polycab India Ltd
(more than 35% returns in just 35 days)
5 September, 2019
Dr Lal PathLabs Limited is a provider of diagnostic and related healthcare tests and services in India.
Dr Lal PathLabs: History
Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre.
The Company was incorporated as Dr Lal PathLabs Private Limited, a private limited company under the Companies Act, 1956, with a certificate of incorporation granted by the RoC on February 14, 1995 at Delhi.
Dr Lal PathLabs: Business Activities
Through its integrated and nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
With over 3,495 diagnostic and related healthcare tests and services offered, the company believe they are capable of performing substantially all of the diagnostic healthcare tests and services currently prescribed by physicians in India.
Dr Lal PathLabs diagnostic and related healthcare tests and services include –
- “Routine” clinical laboratory tests: such as blood chemistry analyses and blood cell counts;
- “Specialized” testing services: such as histopathology analyses, genetic marker-based tests, viral and bacterial cultures and infectious disease tests; and
- “Preventive” testing services: such as screenings for hypertension, heart disease and diabetes.
The Company perform these tests and services in our clinical laboratories using sophisticated and computerized instruments.
Client List
The Company’s customers include individual patients, hospitals and other healthcare providers and corporate customers.
Company Reach
The Company has built a national, hub and spoke network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 191 other clinical laboratories, 2153 patient service centers and 5,624 pickup points as of March 31, 2018.
The Company’s network is present across India, including large cities such as Bengaluru, Chennai, Hyderabad, Kolkata, Mumbai, and New Delhi.
Here is a list of dr lal pathlabs near me
Listed On
The shares of Dr Lal Pathlabs are currently listed at Bombay Stock Exchange (BSE); CODE 539524 and National Stock Exchange (NSE) as LALPATHLAB
Quarterly Numbers
Net profit of Dr Lal Pathlabs rose 19.03 percent to INR 58.80 Cr in the quarter ended June 2019 as against INR 49.40 Cr during the previous quarter ended June 2018.
Sales rose 14.68 percent to INR 335.20 Cr in the quarter ended June 2019 as against INR 292.30 Cr during the previous quarter ended June 2018.
Stock Info – Dr Lal PathLabs
Share Holding Pattern
Financials – Dr Lal PathLabs
Conclusion
Dr Lal PathLabs is NABL certified pathology lab in India.
The Company is among the few Indian laboratories which accredited by CAP (College of American Pathologists) and Certified by ISO 9001 (International Organization of Standardization)
Promoters of the company are having more than 56% stake with zero percent pledge shares.
Along with this, some of the top institution like LO Funds, UTI – Equity Fund, Mirae Asset Emerging Bluechip Fund, Westbridge Crossover Fund, and Franklin India Smaller Companies Fund is having more than 1% stake in the company.
On the technical front, the share price of Dr Lal PathLabs is trading well above its 50 and 200 EMA on the daily chart.
Keeping the above listed points in mind, Dr Lal PathLabs Limited looks good at INR 1234. Finblab recommends investing in the stock in staggered manner for medium to long term.
Value Pick : August 2019
SBI Life Insurance Limited
Disclaimer: The contents and data presented here are just for your information & personal use only. While much effort is made to provide the information, I (Vishal Dalwadi) or “FinBlab” do not guarantee the accuracy, correctness, completeness or reliability of any information or data displayed herein and shall not be held responsible.
